BACKGROUND: Psychiatric disorders are common in HIV patients, and previous work suggests that these patients experience delays in treatment with highly active antiretroviral therapy (HAART). We investigated whether a current psychiatric disorder (1) affected the time to initiation of HAART, (2) predicted the likelihood of being prescribed HAART for at least 6 months, and (3) affected survival in urban AIDS patients. METHODS: We conducted a retrospective cohort study of AIDS patients with no prior history of HAART who were enrolled and followed at the Johns Hopkins University HIV clinic between January 1996 and January 2002. Patients were stratified based on the presence of a psychiatric disorder. Cox proportional hazards regression models estimated the relative risk of receiving HAART and survival, whereas multivariate logistic regression models estimated the relative odds of remaining on HAART. RESULTS: During the study period, 549 patients with AIDS and no prior antiretroviral treatment were enrolled in the clinic. Eighteen percent (n = 100) were defined as having a current psychiatric disorder, 39% (n = 215) were defined as having no psychiatric disorder, and 43% (n = 34) were indeterminate. Patients with a psychiatric disorder were 37% more likely to receive HAART (Cox adjusted hazard ratio [95% confidence interval (CI)]: 1.37 [1.01-1.87]), had greater than twice the odds of being prescribed HAART for at least 6 months (adjusted odds ratio [95% CI]: 2.14 [1.24-3.69]), and were 40% more likely to survive (Cox adjusted hazard ratio [95% CI]: 0.61[0.37-0.99]) as compared with those without a psychiatric disorder. CONCLUSION: Patients with psychiatric disorders are receiving HAART and are able to reap the survival benefit by remaining on it.
BACKGROUND:Psychiatric disorders are common in HIVpatients, and previous work suggests that these patients experience delays in treatment with highly active antiretroviral therapy (HAART). We investigated whether a current psychiatric disorder (1) affected the time to initiation of HAART, (2) predicted the likelihood of being prescribed HAART for at least 6 months, and (3) affected survival in urban AIDSpatients. METHODS: We conducted a retrospective cohort study of AIDSpatients with no prior history of HAART who were enrolled and followed at the Johns Hopkins University HIV clinic between January 1996 and January 2002. Patients were stratified based on the presence of a psychiatric disorder. Cox proportional hazards regression models estimated the relative risk of receiving HAART and survival, whereas multivariate logistic regression models estimated the relative odds of remaining on HAART. RESULTS: During the study period, 549 patients with AIDS and no prior antiretroviral treatment were enrolled in the clinic. Eighteen percent (n = 100) were defined as having a current psychiatric disorder, 39% (n = 215) were defined as having no psychiatric disorder, and 43% (n = 34) were indeterminate. Patients with a psychiatric disorder were 37% more likely to receive HAART (Cox adjusted hazard ratio [95% confidence interval (CI)]: 1.37 [1.01-1.87]), had greater than twice the odds of being prescribed HAART for at least 6 months (adjusted odds ratio [95% CI]: 2.14 [1.24-3.69]), and were 40% more likely to survive (Cox adjusted hazard ratio [95% CI]: 0.61[0.37-0.99]) as compared with those without a psychiatric disorder. CONCLUSION:Patients with psychiatric disorders are receiving HAART and are able to reap the survival benefit by remaining on it.
Authors: Robyn C Neblett; Heidi E Hutton; Bryan Lau; Mary E McCaul; Richard D Moore; Geetanjali Chander Journal: J Womens Health (Larchmt) Date: 2011-01-31 Impact factor: 2.681
Authors: Anthony T Fojo; Catherine R Lesko; Keri L Calkins; Richard D Moore; Mary E McCaul; Heidi E Hutton; William C Mathews; Heidi Crane; Katerina Christopoulos; Karen Cropsey; Michael J Mugavero; Kenneth Mayer; Brian W Pence; Bryan Lau; Geetanjali Chander Journal: AIDS Behav Date: 2019-03
Authors: Nathan B Hansen; Ellen L Vaughan; Courtenay E Cavanaugh; Christian M Connell; Kathleen J Sikkema Journal: Health Psychol Date: 2009-03 Impact factor: 4.267
Authors: Kimberly B Ulett; James H Willig; Hui-Yi Lin; Justin S Routman; Sarah Abroms; Jeroan Allison; Ashlee Chatham; James L Raper; Michael S Saag; Michael J Mugavero Journal: AIDS Patient Care STDS Date: 2009-01 Impact factor: 5.078
Authors: Seth Himelhoch; Clayton H Brown; James Walkup; Geetanjali Chander; P Todd Korthius; Joseph Afful; Kelly A Gebo Journal: AIDS Date: 2009-08-24 Impact factor: 4.177